Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753658 | 0.86 | ALDH1A1 (0.61) | VCAM1MAPTALDH1A1HPGDGAA | |
| SCHEMBL7973732 | 0.83 | VCAM1 (0.68) | VCAM1MAPTALDH1A1HPGDMEN1 | |
| SCHEMBL7981162 | 0.82 | MAPT (0.79) | VCAM1MAPTALDH1A1HPGDGAA | |
| SCHEMBL27967569 | 0.81 | VCAM1 (0.70) | VCAM1MAPTALDH1A1HPGDHTT | |
| SCHEMBL10664878 | 0.81 | HCAR3 (0.67) | MAPTALDH1A1HPGDGAAHTT | |
| SCHEMBL13761390 | 0.81 | MEN1 (0.52) | VCAM1MAPTALDH1A1HPGDGAA | |
| SCHEMBL26418203 | 0.81 | HTT (0.55) | ALDH1A1HPGDGAAHTTMEN1 | |
| SCHEMBL4343389 | 0.81 | ALDH1A1 (0.66) | VCAM1MAPTALDH1A1HPGDGAA | |
| SCHEMBL9196606 | 0.80 | VCAM1 (0.68) | VCAM1MAPTALDH1A1HPGDMEN1 | |
| SCHEMBL51755 | 0.80 | LMNA (0.72) | VCAM1MAPTALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1304382-C | Novel P2X for use in the treatment of inflammatory, immune or cardiovascular diseases7Receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-14 | — | — | CN | disclosed |
| CN-1694876-A | Dibenzoxazepine | BAYER HEALTHCARE AG (DE) | 2005-11-09 | — | — | CN | disclosed |
| US-6812226-B2 | FOR THERAPY OF RHEUMATOID ARTHRITIS, EFFECTING IMMUNOSUPPRESSION | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | disclosed |
| EP-1242396-B1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| CN-1434811-A | Novel P2X for use in the treatment of inflammatory, immune or cardiovascular diseases7Receptor antagonists | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | P2RX1, P2RX2, P2RX3 | VCAM1 299/4885MAPT 4664/4885ALDH1A1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.